194 related articles for article (PubMed ID: 21887218)
21. Therapy for mucopolysaccharidosis VI: (Maroteaux-Lamy syndrome) present status and prospects.
Giugliani R; Herber S; Lapagesse L; de Pinto C; Baldo G
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():152-8. PubMed ID: 25345097
[TBL] [Abstract][Full Text] [Related]
22. Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI.
Giugliani R; Carvalho CG; Herber S; de Camargo Pinto LL
Curr Pharm Biotechnol; 2011 Jun; 12(6):956-62. PubMed ID: 21506914
[TBL] [Abstract][Full Text] [Related]
23. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M
PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051
[TBL] [Abstract][Full Text] [Related]
24. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
Horovitz DD; Magalhães TS; Acosta A; Ribeiro EM; Giuliani LR; Palhares DB; Kim CA; de Paula AC; Kerstenestzy M; Pianovski MA; Costa MI; Santos FC; Martins AM; Aranda CS; Correa Neto J; Holanda GB; Cardoso L; da Silva CA; Bonatti RC; Ribeiro BF; Rodrigues Mdo C; Llerena JC
Mol Genet Metab; 2013 May; 109(1):62-9. PubMed ID: 23535281
[TBL] [Abstract][Full Text] [Related]
25. Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI.
Polgreen LE; Vehe RK; Rudser K; Kunin-Batson A; Utz JJ; Dickson P; Shapiro E; Whitley CB
Mol Genet Metab; 2016 Apr; 117(4):427-30. PubMed ID: 26873528
[TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.
Crawley AC; Brooks DA; Muller VJ; Petersen BA; Isaac EL; Bielicki J; King BM; Boulter CD; Moore AJ; Fazzalari NL; Anson DS; Byers S; Hopwood JJ
J Clin Invest; 1996 Apr; 97(8):1864-73. PubMed ID: 8621770
[TBL] [Abstract][Full Text] [Related]
27. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
Miebach E
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S100-6. PubMed ID: 20040319
[TBL] [Abstract][Full Text] [Related]
28. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
Furujo M; Kubo T; Kosuga M; Okuyama T
Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
[TBL] [Abstract][Full Text] [Related]
29. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
[TBL] [Abstract][Full Text] [Related]
30. Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle.
Tessitore A; Faella A; O'Malley T; Cotugno G; Doria M; Kunieda T; Matarese G; Haskins M; Auricchio A
Mol Ther; 2008 Jan; 16(1):30-7. PubMed ID: 17955027
[TBL] [Abstract][Full Text] [Related]
31. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up.
Furujo M; Kosuga M; Okuyama T
Mol Genet Metab Rep; 2017 Dec; 13():69-75. PubMed ID: 28983456
[TBL] [Abstract][Full Text] [Related]
33. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
34. Liver transplantation: New treatment for mucopolysaccharidosis type VI in rats.
Toyama S; Migita O; Fujino M; Kunieda T; Kosuga M; Fukuhara Y; Nagahara Y; Li XK; Okuyama T
Pediatr Int; 2019 Feb; 61(2):180-189. PubMed ID: 30548979
[TBL] [Abstract][Full Text] [Related]
35. Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI.
Nagpal R; Georgi G; Knauth S; Schmid-Herrmann C; Muschol N; Braulke T; Kahl-Nieke B; Amling M; Schinke T; Koehne T; Petersen J
Front Physiol; 2022; 13():998039. PubMed ID: 36213247
[TBL] [Abstract][Full Text] [Related]
36. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.
Dvorak-Ewell M; Wendt D; Hague C; Christianson T; Koppaka V; Crippen D; Kakkis E; Vellard M
PLoS One; 2010 Aug; 5(8):e12194. PubMed ID: 20808938
[TBL] [Abstract][Full Text] [Related]
37. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).
Hendriksz CJ; Giugliani R; Harmatz P; Lampe C; Martins AM; Pastores GM; Steiner RD; Leão Teles E; Valayannopoulos V;
J Inherit Metab Dis; 2013 Mar; 36(2):373-84. PubMed ID: 22127392
[TBL] [Abstract][Full Text] [Related]
38. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models.
Simonaro CM; D'Angelo M; Haskins ME; Schuchman EH
Pediatr Res; 2005 May; 57(5 Pt 1):701-7. PubMed ID: 15746260
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
40. Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models.
Brooks DA; King BM; Crawley AC; Byers S; Hopwood JJ
Biochim Biophys Acta; 1997 Aug; 1361(2):203-16. PubMed ID: 9300802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
